Britain and America have secured a major trade agreement that will maintain no import taxes on British medicine exports entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on drugs through the NHS. This commitment ensures that import taxes on these key goods will stay at zero for a period of the next three years.
This development comes after previous threats to significantly raise duties on patented pharmaceutical imports, with increases discussed up to double the cost.
"This arrangement with the Britain bolsters the worldwide climate for cutting-edge drugs and brings much-needed equity to transatlantic drug exports," an announcement noted.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's biggest exports to the United States, which is by far the biggest buyer for leading companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to last September, the UK shipped pharmaceutical products worth billions to the US. This value made up a significant portion of British export trade in that span.
"This deal protects employment, increases investment and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Key NHS Changes
The pact involves several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double overall public funding on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be restricted at 15%. Last year, repayments exceeded twenty percent.
Industry Background
This agreement comes amid a ongoing tension between the sector and the ministers over drug pricing and approval rates.
The disagreement were exacerbated by assertions that US patients were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward American operations.
One official acknowledged that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a share of its total funding over the past decade.
